_id
690f36cdccc777a4e85d1795
Ticker
BMEA
Name
Biomea Fusion Inc
Exchange
NASDAQ
Address
1599 Industrial Road, San Carlos, CA, United States, 94070
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://biomeafusion.com
Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Last Close
1.52
Volume
1019012
Current Price
1.41
Change
-7.236842105263164
Last Updated
2025-11-28T13:00:51.736Z
Image
data:image/webp;base64,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
Ipo Date
2021-04-16T00:00:00.000Z
Market Cap
75652896
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.6055
Sentiment Sources
2
Rating
4.2222
Target Price
7
Strong Buy
4
Buy
3
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
20805000
Operating Income
-20805000
Interest Expense
-
Pretax Income
-16407000
Net Income
-16407000
Eps
-0.4038109097761103
Dividends Per Share
-
Shares Outstanding
70703639
Income Tax Expense
-
EBITDA
-15980000
Operating Margin
-
Total Other Income Expense Net
4398000
Cash
46642000
Short Term Investments
-
Receivables
22000
Inventories
-
Total Current Assets
49440000
Property Plant Equipment
5378000
Total Assets
55187000
Payables
6397000
Short Term Debt
787000
Long Term Debt
-
Total Liabilities
39568000
Equity
15619000
Depreciation
400000
Change In Working Capital
4040000
Cash From Operations
-12178000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
2596000
Net Change In Cash
-9582000
PE
-
PB
3.6678960387988986
ROE
-105.04513733273578
ROA
-29.729827676807947
FCF
-12178000
Fcf Percent
-
Piotroski FScore
1
Health Score
24
Deep Value Investing Score
3
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
2.8
Garp Investing Score
0.5
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
3.5
Quality Investing Score
1
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
20805000
Quarters > 0 > income Statement > operating Income
-20805000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-16407000
Quarters > 0 > income Statement > net Income
-16407000
Quarters > 0 > income Statement > eps
-0.4038109097761103
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
40630403
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-15980000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
4398000
Quarters > 0 > balance Sheet > cash
46642000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
22000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
49440000
Quarters > 0 > balance Sheet > property Plant Equipment
5378000
Quarters > 0 > balance Sheet > total Assets
55187000
Quarters > 0 > balance Sheet > payables
6397000
Quarters > 0 > balance Sheet > short Term Debt
787000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
39568000
Quarters > 0 > balance Sheet > equity
15619000
Quarters > 0 > cash Flow > net Income
-16407000
Quarters > 0 > cash Flow > depreciation
400000
Quarters > 0 > cash Flow > change In Working Capital
4040000
Quarters > 0 > cash Flow > cash From Operations
-12178000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
2596000
Quarters > 0 > cash Flow > net Change In Cash
-9582000
Quarters > 0 > ratios > PE
-0.4038109097761103
Quarters > 0 > ratios > PB
3.6678960387988986
Quarters > 0 > ratios > ROE
-105.04513733273578
Quarters > 0 > ratios > ROA
-29.729827676807947
Quarters > 0 > ratios > FCF
-12178000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
24
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
500000
Quarters > 1 > income Statement > gross Profit
-500000
Quarters > 1 > income Statement > operating Expenses
20776000
Quarters > 1 > income Statement > operating Income
-21276000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-20740000
Quarters > 1 > income Statement > net Income
-20740000
Quarters > 1 > income Statement > eps
-0.5104551879537105
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
40630403
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-20240000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
536000
Quarters > 1 > balance Sheet > cash
56224000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
22000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
64663000
Quarters > 1 > balance Sheet > property Plant Equipment
8127000
Quarters > 1 > balance Sheet > total Assets
73163000
Quarters > 1 > balance Sheet > payables
8378000
Quarters > 1 > balance Sheet > short Term Debt
755000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
45653000
Quarters > 1 > balance Sheet > equity
27510000
Quarters > 1 > cash Flow > net Income
-20740000
Quarters > 1 > cash Flow > depreciation
467000
Quarters > 1 > cash Flow > change In Working Capital
-2076000
Quarters > 1 > cash Flow > cash From Operations
-19212000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
39572000
Quarters > 1 > cash Flow > net Change In Cash
20360000
Quarters > 1 > ratios > PE
-0.5104551879537105
Quarters > 1 > ratios > PB
2.082474308615049
Quarters > 1 > ratios > ROE
-75.39076699382042
Quarters > 1 > ratios > ROA
-28.347662069625358
Quarters > 1 > ratios > FCF
-19212000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
33
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
29712000
Quarters > 2 > income Statement > operating Income
-29712000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-29262000
Quarters > 2 > income Statement > net Income
-29262000
Quarters > 2 > income Statement > eps
-0.7989188303710377
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
36627000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-29244000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
450000
Quarters > 2 > balance Sheet > cash
35864000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
24000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
44685000
Quarters > 2 > balance Sheet > property Plant Equipment
9384000
Quarters > 2 > balance Sheet > total Assets
55055000
Quarters > 2 > balance Sheet > payables
7707000
Quarters > 2 > balance Sheet > short Term Debt
1426000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
26318000
Quarters > 2 > balance Sheet > equity
28737000
Quarters > 2 > cash Flow > net Income
-29262000
Quarters > 2 > cash Flow > depreciation
468000
Quarters > 2 > cash Flow > change In Working Capital
-808000
Quarters > 2 > cash Flow > cash From Operations
-25667000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
3252000
Quarters > 2 > cash Flow > net Change In Cash
-22415000
Quarters > 2 > ratios > PE
-0.7989188303710377
Quarters > 2 > ratios > PB
1.7971280927027873
Quarters > 2 > ratios > ROE
-101.82691303893934
Quarters > 2 > ratios > ROA
-53.150485877758605
Quarters > 2 > ratios > FCF
-25667000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
39
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1220000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
1220000
Quarters > 3 > income Statement > operating Expenses
30074000
Quarters > 3 > income Statement > operating Income
-30074000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-29302000
Quarters > 3 > income Statement > net Income
-29302000
Quarters > 3 > income Statement > eps
-0.8079966687440598
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
36265001
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-29605000
Quarters > 3 > income Statement > operating Margin
-2465.0819672131147
Quarters > 3 > income Statement > total Other Income Expense Net
772000
Quarters > 3 > balance Sheet > cash
58279000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
68332000
Quarters > 3 > balance Sheet > property Plant Equipment
10618000
Quarters > 3 > balance Sheet > total Assets
79938000
Quarters > 3 > balance Sheet > payables
12932000
Quarters > 3 > balance Sheet > short Term Debt
2079000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
28365000
Quarters > 3 > balance Sheet > equity
51573000
Quarters > 3 > cash Flow > net Income
-29302000
Quarters > 3 > cash Flow > depreciation
469000
Quarters > 3 > cash Flow > change In Working Capital
-6403000
Quarters > 3 > cash Flow > cash From Operations
-30004000
Quarters > 3 > cash Flow > capital Expenditures
82000
Quarters > 3 > cash Flow > cash From Investing
-82000
Quarters > 3 > cash Flow > cash From Financing
413000
Quarters > 3 > cash Flow > net Change In Cash
-29673000
Quarters > 3 > ratios > PE
-0.8079966687440598
Quarters > 3 > ratios > PB
0.9914810348438136
Quarters > 3 > ratios > ROE
-56.816551296220894
Quarters > 3 > ratios > ROA
-36.655908328954936
Quarters > 3 > ratios > FCF
-30086000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-24.660655737704918
Quarters > 3 > health Score
29
Valuation > metrics > PE
-0.4038109097761103
Valuation > metrics > PB
3.6678960387988986
Valuation > final Score
43.32103961201101
Valuation > verdict
22.3% Overvalued
Profitability > metrics > ROE
-105.04513733273578
Profitability > metrics > ROA
-33.185679611650485
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
2.533324796721941
Risk > metrics > Interest Coverage
-48.723653395784545
Risk > final Score
-177
Risk > verdict
High
Liquidity > metrics > Current Ratio
6.881959910913141
Liquidity > metrics > Quick Ratio
6.881959910913141
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-140
Prev Risks > 1
-6555
Prev Risks > 2
-349
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:17:18.160Z
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AInterim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st
12/11/2025
Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares simplywall.st
Read more →Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 - Stock Titan
12/9/2025
Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 Stock Titan
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$7
Analyst Picks
Strong Buy
4
Buy
3
Hold
2
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 44.82% of the total shares of Biomea Fusion Inc
1.
FMR Inc(12.1729%)
since
2025/06/30
2.
Heights Capital Management Inc(6.4518%)
since
2025/06/30
3.
Cormorant Asset Management, LLC(6.0006%)
since
2025/06/30
4.
Aisling Capital Management LP(3.4428%)
since
2025/06/30
5.
Vanguard Group Inc(3.1587%)
since
2025/06/30
6.
Woodline Partners LP(2.9304%)
since
2025/06/30
7.
Blue Owl Capital Holdings LP(2.1846%)
since
2025/06/30
8.
BlackRock Inc(1.2663%)
since
2025/06/30
9.
Federated Hermes Inc(0.9685%)
since
2025/06/30
10.
Adage Capital Partners Gp LLC(0.8402%)
since
2025/06/30
11.
Millennium Management LLC(0.783%)
since
2025/06/30
12.
Morgan Stanley - Brokerage Accounts(0.6495%)
since
2025/06/30
13.
Burkehill Global Management, LP(0.5882%)
since
2025/06/30
14.
Two Sigma Investments LLC(0.5876%)
since
2025/06/30
15.
AQR Capital Management LLC(0.5686%)
since
2025/06/30
16.
Two Sigma Advisers, LLC(0.4988%)
since
2025/06/30
17.
Geode Capital Management, LLC(0.4601%)
since
2025/06/30
18.
Scotia Capital Inc(0.4285%)
since
2025/06/30
19.
SUPERSTRING CAPITAL MANAGEMENT LP(0.4201%)
since
2025/06/30
20.
UBS Group AG(0.4162%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.